KITCHENER, ON / ACCESS Newswire / March 25, 2025 / Cloud Diagnostics Canada® (Cloud DX®) experienced 100% year-over-year ...

Diagnostics' Q4 2024 earnings insights, FDA resubmissions, TB & HPV test pipelines, and international market growth plans.

Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development ...

Kenworth and Averitt donate, ATA and WIT open nominations for scholarships and awards, and UAF releases a new award.

Based on the notice Samsung published, Han's co-CEO Young-Hyun Jun is now the sole CEO of the company. Jun, who also heads ...

Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the “Company”), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), the Company’s wholly-owned ...

Merlin CP-GEP test delivers high clinical utility - Study prospectively confirms precise risk stratification, optimizing SLNB referral recommendations.High clinical impact in subgroups - Merlin ...

Charles Schwab Investment Management Inc. increased its position in Dynex Capital, Inc. (NYSE:DX – Free Report) by 6.9% in ...

GLEN ALLEN, Va., March 17, 2025--Dynex Capital, Inc. (NYSE: DX) announced today that the Company’s Board of Directors has declared the dividend on shares of its 6.900% Series C Fixed-to-Floating ...

Corient Private Wealth LLC trimmed its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 40.9% during ...

EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry.

The company presented its results this week at a conference and anticipates that with additional validation early next year, it will be ready to file for regulatory approval.